Mondrian Investment Partners LTD lessened its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 18.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,319,087 shares of the company's stock after selling 1,212,908 shares during the period. Kenvue makes up approximately 2.0% of Mondrian Investment Partners LTD's holdings, making the stock its 28th largest position. Mondrian Investment Partners LTD owned about 0.28% of Kenvue worth $113,243,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in KVUE. Grove Bank & Trust grew its holdings in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in Kenvue in the fourth quarter worth about $29,000. SRS Capital Advisors Inc. grew its stake in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC increased its position in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in shares of Kenvue in the 3rd quarter worth approximately $35,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Stock Performance
Kenvue stock traded down $0.07 during mid-day trading on Tuesday, reaching $23.35. 16,840,611 shares of the company traded hands, compared to its average volume of 16,125,580. The firm's fifty day moving average is $21.89 and its two-hundred day moving average is $22.40. The company has a market capitalization of $44.62 billion, a price-to-earnings ratio of 44.05, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.51%. Kenvue's payout ratio is currently 154.72%.
Analyst Ratings Changes
A number of analysts have commented on the stock. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Piper Sandler upped their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and lowered their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Barclays lowered their price objective on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Kenvue has an average rating of "Hold" and a consensus price target of $23.75.
Get Our Latest Stock Analysis on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
